Board of Directors

Christopher B. Begley

Chairman of the Board of Zimmer Biomet Holdings, Inc.
Retired Executive Chairman and Chief Executive Officer, Hospira, Inc.

Christopher B. Begley

Chairman of the Board of Zimmer Biomet Holdings, Inc.
Retired Executive Chairman and Chief Executive Officer, Hospira, Inc.

Director Since 2012 ; Lead Independent Director 2021-2023; Chairman Since 2023

Executive Chairman of the Board of Hospira, Inc. from May 2007 until his retirement in January 2012. Mr. Begley also served as Chief Executive Officer from April 30, 2004, when Hospira was spun off from Abbott Laboratories, to March 2011. Prior to that, Mr. Begley served in various positions with Abbott between 1986 and 2004, most recently as Senior Vice President of Abbott’s Hospital Products division. He earned a bachelor’s degree from Western Illinois University and an MBA from Northern Illinois University.
Other Public Board Memberships

Past director and Non-Executive Chairman of Hanger, Inc. (until October 2022)
Past director and Non-Executive Chairman of Adtalem Global Education Inc. (formerly known as DeVry Education Group Inc.) (until November 2017)

Other Relevant Experience

Past director of the Advanced Medical Technology Association (“AdvaMed”), the medical device industry’s trade association

Member of the Compensation and Management Development Committee
Member of the Corporate Governance Committee

Betsy J. Bernard

Retired President, AT&T Corp.

Betsy J. Bernard

Retired President, AT&T Corp.

Director Since 2009

President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford University’s Sloan Fellowship Program.

Other Public Board Memberships

Past director of Principal Financial Group, Inc. (until June 2020)
Past director of SITO Mobile Ltd. (until June 2017)

Member of the Audit Committee

Chair of the Corporate Governance Committee

Michael J. Farrell

Chairman of the Board and Chief Executive Officer, ResMed Inc.

Michael J. Farrell

Chairman of the Board and Chief Executive Officer, ResMed Inc.

Director Since 2014

Chief Executive Officer of ResMed Inc. since March 2013 and its Chairman of the Board since January 2023. Prior to his appointment as Chief Executive Officer, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Sanofi Genzyme, Dow Chemical and BHP. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management.

Other Public Board Memberships

ResMed Inc.

Other Relevant Experience

Director of AdvaMed

Chair of the Compensation and Management Development Committee

Member of the Quality, Regulatory and Technology Committee

Robert A. Hagemann

Retired Senior Vice President and Chief Financial Officer, Quest Diagnostics Incorporated

Robert A. Hagemann

Retired Senior Vice President and Chief Financial Officer, Quest Diagnostics Incorporated

Director Since 2008

Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated until his retirement in July 2013. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics’ former parent company, Corning Incorporated, in 1992, and held roles of increasing responsibility before being appointed Chief Financial Officer of Quest Diagnostics in 1998. Prior to joining Corning, Mr. Hagemann held senior financial positions at Prime Hospitality, Inc. and Crompton & Knowles, Inc. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University.

Other Public Board Memberships

Graphic Packaging Holding Company
Ryder System, Inc.

Chair of the Audit Committee

Member of the Corporate Governance Committee

Arthur J. Higgins

Operating Advisor to the Abu Dhabi Investment Authority

Arthur J. Higgins

Operating Advisor to the Abu Dhabi Investment Authority

Director Since 2007

Operating Advisor to the Abu Dhabi Investment Authority since June 2021, and Deputy Chairman of the Board of UNION therapeutics A/S since July 2021. Previously, Consultant, Blackstone Healthcare Partners of The Blackstone Group from June 2010 until June 2021. Mr. Higgins served as non-executive chairman of the board of Assertio Holdings, Inc., successor issuer to Assertio Therapeutics, Inc., from May 2020 until December 2020. Prior to that, he served as President, Chief Executive Officer and a member of the board of directors of Assertio Therapeutics, Inc. from March 2017 until its merger with Zyla Life Sciences in May 2020. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry.

Other Public Board Memberships

Ecolab Inc.
Past director of Assertio Holdings, Inc. (until December 2020)
Past director of Assertio Therapeutics, Inc. (until May 2020)
Past director of Endo International plc (until March 2017)

Member of the Compensation and Management Development Committee

Member of the Quality, Regulatory and Technology Committee

Maria Teresa Hilado

Retired Executive Vice President and Chief Financial Officer, Allergan plc

Maria Teresa Hilado

Retired Executive Vice President and Chief Financial Officer, Allergan plc

Director Since 2018

Executive Vice President and Chief Financial Officer of Allergan plc, a global pharmaceutical company, from December 2014 until her retirement in February 2018. Prior to joining Allergan, Ms. Hilado served as Senior Vice President, Finance and Treasurer of PepsiCo Inc. from 2009 until 2014. She previously served as Vice President and Treasurer for Schering-Plough Corp. from 2008 to 2009 and spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including Assistant Treasurer from 2006 to 2008 and Chief Financial Officer, GMAC Commercial Finance LLC from 2001 to 2005. She began her career with Far East Bank and Trust Co. in Manila, Philippines. Ms. Hilado earned a Bachelor’s degree in Management Engineering from Ateneo de Manila University in the Philippines and an MBA from the University of Virginia Darden School of Business.

Other Public Board Memberships

Campbell Soup Company
Past director of H.B. Fuller Company (until December 2021)
Past director of PPD, Inc. (until December 2021)

Member of the Audit Committee
Member of the Corporate Governance Committee

Syed Jafry

Retired Senior Vice President and President, Regions, Thermo Fisher Scientific, Inc.

Syed Jafry

Retired Senior Vice President and President, Regions, Thermo Fisher Scientific, Inc.

Director Since 2018

Retired Senior Vice President and President, Regions, of Thermo Fisher Scientific, Inc. from September 2017 through his retirement in March 2022. Mr. Jafry was responsible for all business geographies outside the U.S. He joined Thermo Fisher Scientific in March 2005 and served in numerous roles of increasing responsibility prior to being appointed to his last position. Mr. Jafry started his career at Glaxo Pharmaceuticals in London. Prior to joining Thermo Fisher Scientific, he served for 18 years at General Electric, where he held commercial, product management and general management roles in the U.S., Netherlands, Switzerland and China, most recently serving as President of GE Sensing Asia. He joined the board of directors of GTCR, LLC, a private equity firm, in 2022. Mr. Jafry holds a Master’s degree in Mechanical Engineering from the University of Massachusetts, a Master’s certificate in Marketing and Management from Harvard University Extension School and a Bachelor’s degree in Mechanical Engineering from Lahore University in Pakistan.

Member of the Compensation and Management Development Committee
Member of the Quality, Regulatory and Technology Committee

Sreelakshmi Kolli

Executive Vice President, Chief Product and Digital Officer, Align Technology, Inc.

Sreelakshmi Kolli

Executive Vice President, Chief Product and Digital Officer, Align Technology, Inc.

Director since 2021

Executive Vice President, Chief Product and Digital Officer of Align Technology, Inc., a global medical device company (“Align”), since December 2023. Ms. Kolli is responsible for Align's product lifecycle, from product ideation and innovation, to engineering, product launch and product performance. This includes leading the product and engineering teams and defining the technology strategy and development of product software, consumer, customer, manufacturing and enterprise applications enabling the Align Digital Platform. Ms. Kolli has led Align’s global business transformation initiative aimed at delivering platforms and technology to support customer experience and simplified business processes across the company. She joined Align in June 2003 and has held positions of increasing responsibility leading and transforming business operations and engineering. She was promoted to Vice President, Information Technology in December 2012, to Senior Vice President, Global Information Technology in February 2018, to Senior Vice President, Chief Digital Officer in April 2020 and to Executive Vice President, Chief Digital Officer, in February 2022. Prior to joining Align, Ms. Kolli held technical lead positions with Citadon and Accenture. She is a member of the board of directors of Intuitive Surgical, Inc. Ms. Kolli earned an M.S. degree in Computer Applications at the National Institute of Technology in Trichy, India and is a graduate of the Stanford Executive Program offered by the Stanford Graduate School of Business in California.

Other Public Board Memberships

Intuitive Surgical Inc.

Member of the Audit Committee

Chair of the Quality, Regulatory and Technology Committee

Devdatt Kurdikar

President, Chief Executive Officer and Director, Embecta Corp.

Devdatt Kurdikar

President, Chief Executive Officer and Director, Embecta Corp.

Director since 2024

President and Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta) since its spinoff from Becton, Dickinson and Company (BD) on April 1, 2022. He was the Worldwide President of Diabetes Care at BD from 2021 until the embecta spinoff. Mr. Kurdikar was President and CEO of Cardiac Science Corporation from 2016 to 2019. He also served with Boston Scientific Corporation, American Medical Systems and Baxter International, Inc. and The Monsanto Company. Mr. Kurdikar holds a Bachelor in Chemical Engineering from the University of Bombay (India), a Master of Science in Chemical Engineering from Washington State University, a Ph.D. in Chemical Engineering from Purdue University and a Master of Business Administration from Washington University.

Other Public Board Memberships

Embecta Corp.

Other Relevant Experience

Director of AdvaMed

Member of the Compensation and Management Development Committee

Member of the Corporate Governance Committee

Louis A. Shapiro

Retired President and Chief Executive Officer, Hospital for Special Surgery

Louis A. Shapiro

Retired President and Chief Executive Officer, Hospital for Special Surgery

Director since 2024

Senior Advisor, General Atlantic since October 2023. President and Chief Executive Officer of the Hospital for Special Surgery (“HSS”), a leading academic medical center focused on musculoskeletal health, from October 2006 until his retirement in October 2023. Prior to joining HSS, Mr. Shapiro worked at Geisinger Health System from 2002 to 2006, serving in roles with increasing leadership scope and ultimately advancing to Executive Vice President and Chief Operating Officer of the Clinical Enterprise. He served as a senior healthcare expert and consultant at McKinsey & Co. from 1999 to 2002 and held positions in other hospitals and health systems from 1983 through 1999. Mr. Shapiro has a bachelor of science degree in psychology from the University of Pittsburgh and a master’s degree in health administration from the University of Pittsburgh Graduate School of Public Health. Mr. Shapiro also has extensive healthcare and nonprofit board service, including serving as a founding member of the board of directors of RightMove Health, as the board chairman of the Greater New York Hospital Association.

Member of the Audit Committee

Member of the Quality, Regulatory and Technology Committee

Ivan Tornos

Director, President and Chief Executive Officer, Zimmer Biomet Holdings, Inc.

Ivan Tornos

Director, President and Chief Executive Officer, Zimmer Biomet Holdings, Inc.

Director Since 2023

Ivan Tornos was appointed President and Chief Executive Officer and a member of the Board of Directors of Zimmer Biomet in August 2023.

Mr. Tornos joined Zimmer Biomet in November 2018 as Group President, Orthopedics, and a year later was named Group President, Global Businesses and the Americas. He was appointed as Chief Operating Officer in March 2021 with responsibility for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global R&D and New Product Development functions. In this role, he had oversight of the Americas and the Europe, Middle East and Africa (EMEA) regions.

Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Division of Becton, Dickinson and Company. Prior to that, he was with C.R. Bard in positions of increasing responsibility, most recently serving as President, Europe, Middle East and Africa Regions. Before joining C.R. Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging segments of Covidien International. Before that, Mr. Tornos served as International Vice President, Business Development and Strategy with Baxter International Inc. and prior to that, he spent over a decade in leadership assignments around the globe with Johnson & Johnson. Mr. Tornos currently serves as an independent member of the Board of Directors of global healthcare company PHC Holdings Corporation.

Mr. Tornos is an alumnus of the Harvard Business School, having graduated from the Advanced Management Program and also completed leadership and management programs at the Cox School of Business of Southern Methodist University. He finalized post-MBA work at the Wharton School of the University of Pennsylvania (CPD Marketing/Finance), holds an MBA from the University of Miami School of Business and a BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business.

ZIMMER BIOMET

345 East Main Street, Warsaw IN 46580

1.800.613.6131

Delivered by IDX – link to website (opens in a new window)